Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in market value. The company briefly touched that level in November but has since returned to about $960 billion.Why has the company been such a mover and shaker in recent times? Lilly sells one of the world's most sought-after drugs: those that help patients lose weight. The pharma giant is the maker of tirzepatide, sold as Zepbound for weight loss and as Mounjaro for type 2 diabetes -- doctors have prescribed either for weight loss. And each of these names has been bringing in billions of dollars in annual revenue.This means that Lilly offers the safety of a pharmaceutical stock along with the growth more often found in other sectors, such as technology. Investors clearly love this combination as Lilly stock has climbed nearly 200% in three years, and as mentioned, market capitalization is approaching $1 trillion. Should you buy Lilly before it reaches that major milestone?Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Eli Lilly und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Eli Lilly
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
